Strategic partnerships Protagenic Therapeutics has recently engaged strategic partners including Floyd Regulatory Strategic Consulting and Danforth Health, presenting opportunities to cross-sell CRO, regulatory affairs, and operations support services to accelerate clinical programs.

Leadership expansion Appointment of Bill Nichols Jr. as President signals a leadership shift and potential need for executive advisory, market expansion planning, and corporate development services to support growth initiatives and capital strategy.

Nascent revenue potential With reported revenue below one million and ongoing clinical development, there is potential for consultative selling around clinical operations, trial management, and data analytics partnerships to de-risk early-stage programs.

Regulatory and compliance focus Nascent regulatory affairs activity and recent regulatory advisory engagements indicate a readiness to collaborate on regulatory strategy, submissions, and continuity planning to navigate approvals and listings.

Financial and market signals Recent Nasdaq delisting concerns coupled with a modest funding base highlight a need for strategic investor relations, financial optimization, and potential partnerships to improve capital efficiency and investor confidence.